Therapeutic options for elderly diabetic subjects: open label, randomized clinical trial of insulin glargine added to oral antidiabetic drugs versus increased dosage of oral antidiabetic drugs

Acta Diabetologica
G PapaV Pezzino

Abstract

Glycemic control in elderly persons with type 2 diabetes mellitus (T2DM) is challenging because they are more likely to have other age-associated medical conditions and to experience hypoglycemia during intensive therapy. A best therapeutic strategy for these patients has not yet been defined. We investigated the efficacy and safety of adding once-daily insulin glargine to patients' current oral antidiabetic drugs (OAD) regimen, compared to increasing the OAD doses. The study enrolled patients aged 65 years or more, with poor glycemic control. Patients were randomized to two groups and entered a 3-week titration period in which their actual therapy was adjusted to meet the study's glycemic goals, by either adding insulin glargine to current therapy (group A, 27 patients) or increasing current OAD dosages (group B, 28 patients). Thereafter, therapies were continued unchanged for a 24-week observation period. The mean therapeutic dosage of insulin glargine in group A was 14.9 IU/day (SD = 5.0 IU/day). During the observation period, mean levels of glycosylated hemoglobin (HbA1c) reduced by 1.5% in group A and 0.6% in group B (P = 0.381). An HbA1c level <7.0% was achieved by five patients in each group. Mean fasting blood glucose l...Continue Reading

References

Jun 1, 1990·Diabetes Care·M C Riddle
Oct 1, 1995·Diabetes/metabolism Reviews·U Di MarioG Pozzessere
Sep 12, 2000·Lancet·G B Bolli, D R Owens
Apr 16, 2003·Journal of the American Geriatrics Society·Arlene F BrownUNKNOWN California Healthcare Foundation/American Geriatrics Society Panel on Improving Care for Elders with Diabetes
Oct 2, 2003·Experimental and Clinical Endocrinology & Diabetes : Official Journal, German Society of Endocrinology [and] German Diabetes Association·A HolsteinE-H Egberts
Oct 28, 2003·Diabetes Care·Matthew C RiddleUNKNOWN Insulin Glargine 4002 Study Investigators

❮ Previous
Next ❯

Citations

Apr 12, 2013·Cardiovascular Diabetology·Diethelm TschöpePetra-Maria Schumm-Draeger
Apr 4, 2012·CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne·Adrian N C LauCatherine H Y Yu
Aug 7, 2009·Wiener klinische Wochenschrift·Bernhard LudvikUNKNOWN Expertengruppe der Osterreichischen Diabetesgesellschaft
Nov 18, 2011·Expert Opinion on Pharmacotherapy·Edoardo MannucciAndrea Rossi
Aug 6, 2008·Expert Opinion on Drug Metabolism & Toxicology·M A ElrishiM J Davies
May 16, 2014·Canadian Journal of Diabetes·Graydon S MeneillyDaniel Tessier
Sep 6, 2011·Maturitas·Kyaw SoeGül Bahtiyar
Apr 5, 2011·The American Journal of Geriatric Pharmacotherapy·Lal K Tanwani
Aug 14, 2012·Journal of the American Geriatrics Society·Robert J LigthelmJean-François Yale
May 9, 2015·Journal of the American Geriatrics Society·Rituparna BhattacharyaUsha Sambamoorthi
Dec 8, 2014·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Supriya MathurBrian M Frier
Mar 17, 2009·Expert Opinion on Pharmacotherapy·Stanislav GoykhmanMarc Rendell
Dec 6, 2008·Current Opinion in Clinical Nutrition and Metabolic Care
Dec 25, 2008·Current Opinion in Lipidology
Mar 21, 2009·Current Opinion in Endocrinology, Diabetes, and Obesity

❮ Previous
Next ❯

Related Concepts

Related Feeds

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.